<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440595</url>
  </required_header>
  <id_info>
    <org_study_id>5172-012</org_study_id>
    <secondary_id>2011-003299-36</secondary_id>
    <nct_id>NCT01440595</nct_id>
  </id_info>
  <brief_title>Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)</brief_title>
  <official_title>A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir
      (MK-5172) when administered concomitantly with peg-interferon alfa-2b (Peg-IFN) and ribavirin
      (RBV) to treatment-naïve participants with chronic genotype 2 (GT2) or genotype 3 (GT3)
      hepatitis C virus (HCV) infections.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to
    elevated transaminase levels in treatment with grazoprevir.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Complete Early Virologic Response (cEVR) in the Grazoprevir Treatment Arms</measure>
    <time_frame>Week 12</time_frame>
    <description>cEVR was defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v.2.0 assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Achievement of Undetectable HCV Ribonucleic Acid (RNA)</measure>
    <time_frame>Baseline to Week 12 for Grazoprevir treatment arms, Week 24 for Placebo arm</time_frame>
    <description>Time to first achievement of undetectable HCV RNA was determined by measuring HCV RNA at Treatment Days 1, 3, and 7; Treatment Weeks 2, 4, 8, 12, 16, 20, and 24; as well as Follow-up Weeks 4, 12, and 24. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Rapid Viral Response (RVR)</measure>
    <time_frame>Week 4</time_frame>
    <description>RVR was defined as undetectable HCV RNA at Week 4. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Sustained Viral Response 12 Weeks After Completion of Therapy (SVR12)</measure>
    <time_frame>Week 24 for Grazoprevir treatment arms, Week 36 for Placebo arm</time_frame>
    <description>SVR12 was defined as undetectable HCV RNA 12 weeks after completion of study therapy. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Sustained Viral Response 24 Weeks After Completion of Therapy (SVR24)</measure>
    <time_frame>Week 36 for Grazoprevir treatment arms, Week 48 for Placebo arm</time_frame>
    <description>SVR24 was defined as undetectable HCV RNA 24 weeks after completion of study therapy. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Undetectable HCV RNA at Week 12 in the Placebo Arm</measure>
    <time_frame>Week 12</time_frame>
    <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Complete Early Virologic Response (cEVR) at Week 24 in the Placebo Arm</measure>
    <time_frame>Week 24</time_frame>
    <description>cEVR was defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 24 (i.e., after 12 weeks of placebo + 12 weeks of grazoprevir treatment). HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Grazoprevir 200 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 400 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Peg-IFN + RBV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grazoprevir 800 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir</intervention_name>
    <description>Grazoprevir 100 mg tablets once daily for 12 weeks.</description>
    <arm_group_label>Grazoprevir 200 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg + Peg-IFN + RBV</arm_group_label>
    <other_name>MK-5172</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Grazoprevir</intervention_name>
    <description>Placebo to Grazoprevir once daily for 12 weeks</description>
    <arm_group_label>Placebo + Peg-IFN + RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2b (Peg-IFN)</intervention_name>
    <description>Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks</description>
    <arm_group_label>Grazoprevir 200 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Placebo + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg + Peg-IFN + RBV</arm_group_label>
    <other_name>PegIntron®, SCH 054031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks</description>
    <arm_group_label>Grazoprevir 200 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Grazoprevir 400 mg + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Placebo + Peg-IFN + RBV</arm_group_label>
    <arm_group_label>Grazoprevir 800 mg + Peg-IFN + RBV</arm_group_label>
    <other_name>Rebetol®, SCH 018908</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight ≥ 88 lbs and ≤ 275 lbs

          -  Documented chronic Hepatitis C (CHC) GT2 or GT3 infection

          -  No known cirrhosis

          -  Agrees to use two acceptable methods of birth control during study and through 6
             months after last dose of study drug

          -  Chest X-ray within the last 6 months

          -  Eye exam within the last 6 months

        Exclusion Criteria:

          -  Known to be human immunodeficiency virus (HIV) positive or co-infected with active
             hepatitis B virus (positive for Hepatitis B surface antigen)

          -  Prior approved or investigational treatment for hepatitis C

          -  Evidence of hepatocellular carcinoma

          -  Diabetic and/or high blood pressure with clinically significant eye exam findings

          -  Pre-existing psychiatric condition

          -  Clinical diagnosis of abuse of certain substances within specified timeframes

          -  Known medical condition that could interfere with participation

          -  Active or suspected cancer within the last 5 years

          -  Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs

          -  Male who is planning to impregnate partner or donate sperm

          -  Male with a pregnant female partner

          -  Chronic hepatitis not caused by HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
    <country>Norway</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <results_first_submitted>February 3, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2016</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=5172-012&amp;kw=5172-012&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No participants were randomized to the Grazoprevir 800 mg + Peg-IFN + RBV arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Grazoprevir 200 mg + Peg-IFN + RBV</title>
          <description>Grazoprevir 200 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
          <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo + Peg-IFN + RBV</title>
          <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Five participants were randomized as indicated in the Participant Flow Module, but only 3 participants were treated. Baseline Characteristics are presented only for treated participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
          <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Peg-IFN + RBV</title>
          <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="7.8"/>
                    <measurement group_id="B2" value="51.0" spread="0.0"/>
                    <measurement group_id="B3" value="44.0" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Complete Early Virologic Response (cEVR) in the Grazoprevir Treatment Arms</title>
        <description>cEVR was defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v.2.0 assay.</description>
        <time_frame>Week 12</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
            <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Peg-IFN + RBV</title>
            <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Complete Early Virologic Response (cEVR) in the Grazoprevir Treatment Arms</title>
          <description>cEVR was defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v.2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Achievement of Undetectable HCV Ribonucleic Acid (RNA)</title>
        <description>Time to first achievement of undetectable HCV RNA was determined by measuring HCV RNA at Treatment Days 1, 3, and 7; Treatment Weeks 2, 4, 8, 12, 16, 20, and 24; as well as Follow-up Weeks 4, 12, and 24. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>Baseline to Week 12 for Grazoprevir treatment arms, Week 24 for Placebo arm</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
            <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Peg-IFN + RBV</title>
            <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Achievement of Undetectable HCV Ribonucleic Acid (RNA)</title>
          <description>Time to first achievement of undetectable HCV RNA was determined by measuring HCV RNA at Treatment Days 1, 3, and 7; Treatment Weeks 2, 4, 8, 12, 16, 20, and 24; as well as Follow-up Weeks 4, 12, and 24. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Rapid Viral Response (RVR)</title>
        <description>RVR was defined as undetectable HCV RNA at Week 4. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>Week 4</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
            <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Peg-IFN + RBV</title>
            <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Rapid Viral Response (RVR)</title>
          <description>RVR was defined as undetectable HCV RNA at Week 4. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Sustained Viral Response 12 Weeks After Completion of Therapy (SVR12)</title>
        <description>SVR12 was defined as undetectable HCV RNA 12 weeks after completion of study therapy. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>Week 24 for Grazoprevir treatment arms, Week 36 for Placebo arm</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
            <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Peg-IFN + RBV</title>
            <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Sustained Viral Response 12 Weeks After Completion of Therapy (SVR12)</title>
          <description>SVR12 was defined as undetectable HCV RNA 12 weeks after completion of study therapy. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Sustained Viral Response 24 Weeks After Completion of Therapy (SVR24)</title>
        <description>SVR24 was defined as undetectable HCV RNA 24 weeks after completion of study therapy. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>Week 36 for Grazoprevir treatment arms, Week 48 for Placebo arm</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
            <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Peg-IFN + RBV</title>
            <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Sustained Viral Response 24 Weeks After Completion of Therapy (SVR24)</title>
          <description>SVR24 was defined as undetectable HCV RNA 24 weeks after completion of study therapy. HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Undetectable HCV RNA at Week 12 in the Placebo Arm</title>
        <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>Week 12</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
            <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Peg-IFN + RBV</title>
            <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Undetectable HCV RNA at Week 12 in the Placebo Arm</title>
          <description>HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Complete Early Virologic Response (cEVR) at Week 24 in the Placebo Arm</title>
        <description>cEVR was defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 24 (i.e., after 12 weeks of placebo + 12 weeks of grazoprevir treatment). HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
            <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Peg-IFN + RBV</title>
            <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Complete Early Virologic Response (cEVR) at Week 24 in the Placebo Arm</title>
          <description>cEVR was defined as undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 24 (i.e., after 12 weeks of placebo + 12 weeks of grazoprevir treatment). HCV RNA was measured using the Roche COBAS® Taqman® HCV Test, v2.0 assay.</description>
          <population>The Full Analysis Set (FAS) population includes all randomized participants who received at least 1 dose of study treatment. No participants completed treatment, and no analyses were conducted for this study due to early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious AEs were collected up to Week 26 and serious AEs (SAEs) were collected up to Week 48.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Grazoprevir 400 mg + Peg-IFN + RBV</title>
          <description>Grazoprevir 400 mg once daily by mouth in combination with Peg-IFN and RBV for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Peg-IFN + RBV</title>
          <description>Placebo to grazoprevir once daily by mouth in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v. 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Irritabilty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Restless leg syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

